Immunitybio (NASDAQ: IBRX) — Perfil da empresa, notícias e dados financeiros
Immunitybio develops therapies to enhance the immune system's response to cancer and infectious diseases.
Immunitybio
Immunitybio is a clinical-stage biotechnology company that develops next-generation immunotherapies and vaccines designed to treat cancers and infectious diseases. The company focuses on orchestrating both innate and adaptive immune responses using cytokine fusion proteins, natural killer cell therapies, and therapeutic vaccines. Its primary FDA-approved product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an IL-15 receptor agonist indicated in combination with Bacillus Calmette-Guérin for non-muscle invasive bladder cancer. ImmunityBio conducts clinical trials across multiple oncological indications, including bladder, lung, head and neck, and ovarian cancers, as well as viral infectious diseases.
Resumo
Operações
Produtos e/ou serviços de Immunitybio
- Bladder Cancer Immunotherapies: An FDA-approved IL-15 receptor agonist complex administered in combination with Bacillus Calmette-Guérin for patients with BCG-unresponsive non-muscle invasive bladder cancer, with ongoing trials evaluating use in BCG-naïve patient populations.
- Cytokine Fusion Proteins: Proprietary IL-15 superagonist platforms engineered to activate and proliferate natural killer cells and CD8+ T cells without expanding immunosuppressive regulatory T cells, supporting combination therapies across multiple solid tumors.
- Natural Killer Cell Platforms: Allogeneic off-the-shelf natural killer cell lines, including high-affinity NK cells and targeted chimeric antigen receptor NK cells, designed to destroy targeted tumor cells and infected tissues in clinical settings.
- Therapeutic Cancer Vaccines: Viral vector platforms, including human adenovirus serotype 5 constructs, designed to deliver tumor-associated antigens and elicit targeted cytotoxic T-cell responses against advanced solid tumors and viral pathogens.
- Non-Small Cell Lung Cancer Programs: Late-stage clinical developments combining cytokine superagonists with immune checkpoint inhibitors and targeted therapies to evaluate survival outcomes in patients with advanced or metastatic non-small cell lung cancer.
- Biomanufacturing Infrastructure: In-house manufacturing and quality control facilities located across Southern California, Washington, and Colorado that produce clinical and commercial grade biologics, cell therapies, and viral vectors.
equipe executiva do Immunitybio
- Patrick Soon-ShiongFounder, Executive Chairman and Global Chief Scientific & Medical Officer
- Richard Gerald AdcockPresident, CEO & Director
- David C. SachsChief Financial Officer
- Regan J. LauerChief Accounting Officer
- Barry J. SimonChief Corporate Affairs Officer & Director
- Enrique DilonéChief Technology Officer
- Sarah SingletonChief Communications Officer & Head of Patient Advocacy
- Emily ArisonSenior Vice President of Human Resources
- Leonard S. SenderChief Medical Officer of Liquid Tumors & Cell Therapy
- Sandeep K. ReddyChief Medical Officer
Últimas notícias sobre a Immunitybio
ImmunityBio data highlights highly individualized patient priorities in bladder cancer care
United StatesImmunityBio bladder cancer therapy accepted for FDA review to expand label
United StatesImmunityBio posts 168% revenue surge as ANKTIVA adoption accelerates
United StatesImmunityBio surges as ANKTIVA revenue jumps 700% in breakthrough 2025
United StatesImmunityBio initiates phase 2 "chemo-free" lymphoma trial
United StatesImmunityBio’s chemo-free regimen shows survival promise in deadly brain cancer
United States
Principais indicadores financeiros
Resultados divulgados pela Immunitybio, em USD.
- Cap. de mercado
- 9,1 bi
- Receita (TTM)
- 165,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 113,3 mi | -256 mi | -351,4 mi | |
| 14,7 mi | -344,2 mi | -413,6 mi | |
| 622 mil | -362,3 mi | -583,2 mi | |
| 240 mil | -351,3 mi | -416,6 mi |